{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:25:41Z","timestamp":1788297941298,"version":"build-2803163510"},"reference-count":108,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jsat.2020.01.009","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T12:13:07Z","timestamp":1579608787000},"page":"54-66","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders"],"prefix":"10.1016","volume":"111","author":[{"given":"Elizabeth C.","family":"Saunders","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Metcalf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan J.","family":"Budney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Scherer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Marsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jsat.2020.01.009_bb0005","first-page":"560","article-title":"Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label phase 1 study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Advanced Therapeutics"},{"key":"10.1016\/j.jsat.2020.01.009_bb0010","first-page":"1","article-title":"Underutilization of medications to treat opioid use disorder: What role does stigma play?","author":"Allen","year":"2019","journal-title":"Substance Abuse"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0015","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.jsat.2011.01.009","article-title":"Injection drug users\u2019 experience with and attitudes toward methadone clinics in Denver, CO","volume":"41","author":"Al-Tayyib","year":"2011","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0020","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00000542-200603000-00025","article-title":"Opioid-induced hyperalgesia: A qualitative systematic review","volume":"104","author":"Angst","year":"2006","journal-title":"Anesthesiology"},{"key":"10.1016\/j.jsat.2020.01.009_bb0025","doi-asserted-by":"crossref","DOI":"10.1177\/2045125316681984","article-title":"Probuphine\u00ae (buprenorphine implant): A promising candidate in opioid dependence","author":"Barnwal","year":"2017","journal-title":"Therapeutic Advances in Psychopharmacology"},{"issue":"7","key":"10.1016\/j.jsat.2020.01.009_bb0030","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1111\/j.1360-0443.2009.02627.x","article-title":"Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Addiction"},{"issue":"10182","key":"10.1016\/j.jsat.2020.01.009_bb0035","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(18)33078-2","article-title":"Management of opioid use disorder in the USA: Present status and future directions","volume":"393","author":"Blanco","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0040","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1136\/jamia.1998.0050257","article-title":"Improving health care by understanding patient preferences: The role of computer technology","volume":"5","author":"Brennan","year":"1998","journal-title":"Journal of the American Medical Informatics Association"},{"issue":"9","key":"10.1016\/j.jsat.2020.01.009_bb0045","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1176\/appi.ps.52.9.1230","article-title":"Patient satisfaction, use of services, and one-year outcomes in publicly funded substance abuse treatment","volume":"52","author":"Carlson","year":"2001","journal-title":"Psychiatric Services"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1046\/j.1360-0443.1999.9433273.x","article-title":"Meta-analysis of cue-reactivity in addiction research","volume":"94","author":"Carter","year":"1999","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2020.01.009_bb0055","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.jsat.2020.01.009_bb0060","unstructured":"Centers for Disease Control and Prevention (CDC). (2018, December 19, 2018). Drug overdose deaths. Retrieved from https:\/\/www.cdc.gov\/drugoverdose\/data\/statedeaths.html"},{"key":"10.1016\/j.jsat.2020.01.009_bb0065","unstructured":"Centers for Disease Control and Prevention (CDC). (2019a, January 2019). Overdose death rates. Retrieved from https:\/\/www.drugabuse.gov\/related-topics\/trends-statistics\/overdose-death-rates"},{"key":"10.1016\/j.jsat.2020.01.009_bb0070","author":"Centers for Disease Control and Prevention (CDC)"},{"key":"10.1016\/j.jsat.2020.01.009_bb0075","first-page":"73","article-title":"Cue reactivity and cue reactivity interventions in drug dependence","volume":"137","author":"Childress","year":"1993","journal-title":"NIDA Research Monographs"},{"issue":"8","key":"10.1016\/j.jsat.2020.01.009_bb0080","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s11606-009-0987-8","article-title":"How well do guidelines incorporate evidence on patient preferences?","volume":"24","author":"Chong","year":"2009","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2020.01.009_bb0085","series-title":"Drug misuse and dependence: UK guidelines on clinical management","author":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group","year":"2017"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0090","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpain.2012.01.001","article-title":"Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy","volume":"13","author":"Compton","year":"2012","journal-title":"The Journal of Pain"},{"issue":"8","key":"10.1016\/j.jsat.2020.01.009_bb0095","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1111\/add.12536","article-title":"The impact of opioid substitution therapy on mortality post-release from prison: Retrospective data linkage study","volume":"109","author":"Degenhardt","year":"2014","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s11469-012-9402-5","article-title":"Drug addiction stigma in the context of methadone maintenance therapy: An investigation into understudied sources of stigma","volume":"11","author":"Earnshaw","year":"2013","journal-title":"Int Journal of Menttal Health and Addiction"},{"issue":"10","key":"10.1016\/j.jsat.2020.01.009_bb0105","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1007\/s11606-012-2077-6","article-title":"Shared decision making: A model for clinical practice","volume":"27","author":"Elwyn","year":"2012","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2020.01.009_bb0110","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.yebeh.2015.10.006","article-title":"Moving beyond evidence-based medicine: Incorporating patient values and preferences","volume":"53","author":"Fallah","year":"2015","journal-title":"Epilepsy and Behavior"},{"key":"10.1016\/j.jsat.2020.01.009_bb0115","author":"Fischer"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145817","article-title":"Patient preferences and shared decision making in the treatment of substance use disorders: A systematic review of the literature","volume":"11","author":"Friedrichs","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jsat.2020.01.009_bb0125","doi-asserted-by":"crossref","unstructured":"Frost, M., Bailey, G. L., Lintzeris, N., Strang, J., Dunlop, A., Nunes, E. V., \u2026 Tiberg, F. (2019). Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. Addiction. doi:https:\/\/doi.org\/10.1111\/add.14636.","DOI":"10.1111\/add.14636"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0130","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1360-0443.2007.02090.x","article-title":"Exposure to opioid maintenance treatment reduces long-term mortality","volume":"103","author":"Gibson","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2020.01.009_bb0135","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: A survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"Gilman","year":"2018","journal-title":"Patient Preferences and Adherence"},{"key":"10.1016\/j.jsat.2020.01.009_bb0140","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough? An experiment with data saturation and variability","volume":"18","author":"Guest","year":"2006","journal-title":"Field Methods"},{"issue":"12","key":"10.1016\/j.jsat.2020.01.009_bb0145","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.socscimed.2007.02.049","article-title":"Buprenorphine substitution treatment in France: Drug users\u2019 views of the doctor-user relationship","volume":"64","author":"Guichard","year":"2007","journal-title":"Social Science and Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0150","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/1468-0009.00223","article-title":"Trust in physicians and medical institutions: What is it, can it be measured, and does it matter?","volume":"79","author":"Hall","year":"2001","journal-title":"Milbank Quarterly"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0155","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/maq.12232","article-title":"To be free and normal: Addiction, governance, and the therapeutics of buprenorphine","volume":"29","author":"Harris","year":"2015","journal-title":"Medical Anthropology Quarterly"},{"key":"10.1016\/j.jsat.2020.01.009_bb0160","unstructured":"Indivior. (2017a, November 30, 2017). FDA approves Sublocade (buprenorphine extended-release), the first and only once-monthly injectable buprenorphine formulation to treat moderate to severe opioid use disorder. Retrieved from http:\/\/www.indivior.com\/investor-news\/fda-approves-sublocade-buprenorphine-extended-release-first-monthly-injectable-buprenorphine-formulation-treat-moderate-severe-opioid-use-disorder\/"},{"key":"10.1016\/j.jsat.2020.01.009_bb0165","author":"Indivior"},{"key":"10.1016\/j.jsat.2020.01.009_bb0170","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.2147\/DDDT.S109331","article-title":"New developments in managing opioid addiction: Impact of a subdermal buprenorphine implant","volume":"11","author":"Itzoe","year":"2017","journal-title":"Drug Design, Development and Therapy"},{"issue":"8","key":"10.1016\/j.jsat.2020.01.009_bb0175","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3109\/10826084.2011.552931","article-title":"Shared decision-making: Increases autonomy in substance-dependent patients","volume":"46","author":"Joosten","year":"2011","journal-title":"Substance Use and Misuse"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0180","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000126073","article-title":"Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status","volume":"77","author":"Joosten","year":"2008","journal-title":"Psychotherapy and Psychosomatics"},{"issue":"16","key":"10.1016\/j.jsat.2020.01.009_bb0185","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2009.1550","article-title":"Patient-centered care and preference-sensitive decision making","volume":"302","author":"Keirns","year":"2009","journal-title":"The Journal of the American Medical Association (JAMA)"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3109\/00952990.2011.643983","article-title":"A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients","volume":"38","author":"Kelly","year":"2012","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/00952991003736371","article-title":"The role of patient satisfaction in methadone treatment","volume":"36","author":"Kelly","year":"2010","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2020.01.009_bb0200","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jsat.2018.08.011","article-title":"Buprenorphine treatment formulations: Preferences among persons in opioid withdrawal management","volume":"94","author":"Kenney","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13561-016-0094-6","article-title":"Patient- and person-reports on healthcare: Preferences, outcomes, experiences, and satisfaction - an essay","volume":"6","author":"Klose","year":"2016","journal-title":"Health Economics Review"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0210","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/jama.300.4.436","article-title":"The next step in guideline development: Incorporating patient preferences","volume":"300","author":"Krahn","year":"2008","journal-title":"Journal of the American Medical Association (JAMA)"},{"issue":"9","key":"10.1016\/j.jsat.2020.01.009_bb0215","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1111\/add.12208","article-title":"Injectable extended-release naltrexone (XR-NTX) for opioid dependence: Long-term safety and effectiveness","volume":"108","author":"Krupitsky","year":"2013","journal-title":"Addiction"},{"issue":"9776","key":"10.1016\/j.jsat.2020.01.009_bb0220","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: A double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"The Lancet"},{"key":"10.1016\/j.jsat.2020.01.009_bb0225","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jsat.2019.06.001","article-title":"Brief video intervention to improve attitudes throughout medications for opioid use disorder in a correctional setting","volume":"104","author":"Lam","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.01.009_bb0230","series-title":"Paper presented at the College of Problems on Drug Dependence (CPDD), Montreal, CA","article-title":"RBP-6000 buprenorphine monthly depot demonstrates efficacy, safety and exposure-response relationship in opioid use disorder","author":"Learned","year":"2017"},{"issue":"2","key":"10.1016\/j.jsat.2020.01.009_bb0235","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1377\/hlthaff.2012.1078","article-title":"Shared decision making: Examining key elements and barriers to adoption into routine clinical practice","volume":"32","author":"Legare","year":"2013","journal-title":"Health Affairs"},{"issue":"14","key":"10.1016\/j.jsat.2020.01.009_bb0240","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1001\/jama.2010.1427","article-title":"Buprenorphine implants for treatment of opioid dependence: A randomized controlled trial","volume":"304","author":"Ling","year":"2010","journal-title":"The Journal of the American Medical Association (JAMA)"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0245","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2217\/pmt.12.26","article-title":"Buprenorphine for opioid addiction","volume":"2","author":"Ling","year":"2012","journal-title":"Pain Management"},{"key":"10.1016\/j.jsat.2020.01.009_bb0250","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1747-597X-8-29","article-title":"Assessment of attitudes towards methadone maintenance treatment between heroin users at a compulsory detoxification centre and methadone maintenance clinic in Ningbo, China","volume":"8","author":"Liu","year":"2013","journal-title":"Substace Abuse Treatment, Prevention and Policy"},{"key":"10.1016\/j.jsat.2020.01.009_bb0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.36076\/ppj.2012\/15\/ES9","article-title":"Opioid epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"issue":"10","key":"10.1016\/j.jsat.2020.01.009_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022267","article-title":"Patient engagement, treatment preferences and shared decision-making in the treatment of opioid use disorder in adults: A scoping review protocol","volume":"8","author":"Marshall","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jsat.2020.01.009_bb0265","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1016\/j.jsat.2020.01.009_bb0270","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1080\/10826084.2017.1342662","article-title":"Medication-assisted treatment for opioid addiction in the United States: Critique and commentary","volume":"53","author":"McElrath","year":"2018","journal-title":"Substance Use and Misuse"},{"issue":"10","key":"10.1016\/j.jsat.2020.01.009_bb0275","doi-asserted-by":"crossref","first-page":"690","DOI":"10.7326\/M16-0317","article-title":"Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) tool for substance use screening in primary care patients","volume":"165","author":"McNeely","year":"2016","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0280","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1363461516660884","article-title":"Shifting blame: Buprenorphine prescribers, addiction treatment, and prescription monitoring in middle-class America","volume":"53","author":"Mendoza","year":"2016","journal-title":"Transcultural Psychiatry"},{"issue":"5","key":"10.1016\/j.jsat.2020.01.009_bb0285","first-page":"327","article-title":"Mutual mistrust in the medical care of drug users: The keys to the \u201cnarc\u201d cabinet","volume":"17","author":"Merrill","year":"2002","journal-title":"Journal of General Internal Medicine"},{"issue":"2","key":"10.1016\/j.jsat.2020.01.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010035","article-title":"Medication-related burden and patients\u2019 lived experience with medicine: A systematic review and metasynthesis of qualitative studies","volume":"6","author":"Mohammed","year":"2016","journal-title":"BMJ Open"},{"issue":"23","key":"10.1016\/j.jsat.2020.01.009_bb0295","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1001\/jama.2013.281422","article-title":"The optimal practice of evidence-based medicine: Incorporating patient preferences in practice guidelines","volume":"310","author":"Montori","year":"2013","journal-title":"Journal of the American Medical Association (JAMA)"},{"issue":"11","key":"10.1016\/j.jsat.2020.01.009_bb0300","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1111\/pme.12200","article-title":"Patients as collaborators: Using focus groups and feedback sessions to develop an interactive, web-based self-management intervention for chronic pain","volume":"14","author":"Moore","year":"2013","journal-title":"Pain Medicine"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0305","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/10826084.2013.832328","article-title":"\u201cThis is not who I want to be:\u201d Experiences of opioid-dependent youth before, and during, combined buprenorphine and behavioral treatment","volume":"49","author":"Moore","year":"2014","journal-title":"Substance Use and Misuse"},{"key":"10.1016\/j.jsat.2020.01.009_bb0310","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jsat.2017.07.001","article-title":"Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population","volume":"85","author":"Morgan","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.01.009_bb0315","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jsat.2019.01.019","article-title":"Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support","volume":"100","author":"Muthulingam","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.01.009_bb0320","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fnbeh.2018.00017","article-title":"The winding road to relapse: Forging a new understanding of cue-induced reinstatement models and their associated neural mechanisms","volume":"12","author":"Namba","year":"2018","journal-title":"Frontiers in Behavioral Neuroscience"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0325","first-page":"18","article-title":"Sustained-release buprenorphine (RBP-6000) blocks the effects of opioid challenge with hydromorphone in subjects with opioid use disorder","volume":"36","author":"Nasser","year":"2016","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.jsat.2020.01.009_bb0330","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"10.1016\/j.jsat.2020.01.009_bb0335","series-title":"Express scribe transcription software, version 5.87","author":"NCH Software","year":"2016"},{"key":"10.1016\/j.jsat.2020.01.009_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.jsat.2020.01.009_bb0345","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1037\/pha0000217","article-title":"Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making","volume":"26","author":"Neale","year":"2018","journal-title":"Experimental and Clinical Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0350","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12954-019-0296-4","article-title":"Prolonged-release opioid agonist therapy: Qualitative study exploring patients\u2019 views of 1-week, 1-month, and 6-month buprenorphine formulations","volume":"16","author":"Neale","year":"2019","journal-title":"Harm Reduction Journal"},{"issue":"5","key":"10.1016\/j.jsat.2020.01.009_bb0355","article-title":"Opioid agonist treatment for pharmaceutical opioid dependent people","author":"Nielsen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0360","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/ADM.0000000000000125","article-title":"Treating opioid dependence with injectable extended-release naltrexone (XR-NTX): Who will respond?","volume":"9","author":"Nunes","year":"2015","journal-title":"Journal of Addiction Medicine"},{"issue":"14","key":"10.1016\/j.jsat.2020.01.009_bb0365","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1001\/jama.2014.2147","article-title":"Confronting the stigma of opioid use disorder and its treatment","volume":"311","author":"Olsen","year":"2014","journal-title":"Journal of the American Medical Association (JAMA)"},{"key":"10.1016\/j.jsat.2020.01.009_bb0370","author":"Pharmaceuticals"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0375","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jsat.2010.07.009","article-title":"The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment","volume":"39","author":"Pinto","year":"2010","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.01.009_bb0380","article-title":"Comparing reasons for starting and stopping methadone, buprenorphine, and naltrexone treatment among a sample of white individuals with opioid use disorder","author":"Randall-Kosich","year":"2019","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.01.009_bb0385","series-title":"The healing of America: A global quest for better, cheaper and fairer health care","author":"Reid","year":"2010"},{"issue":"2","key":"10.1016\/j.jsat.2020.01.009_bb0390","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jsat.2006.09.002","article-title":"Client and counselor attitudes toward the use of medications for treatment of opioid dependence","volume":"32","author":"Rieckmann","year":"2007","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"12","key":"10.1016\/j.jsat.2020.01.009_bb0395","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/add.12315","article-title":"Buprenorphine implants for treatment of opioid dependence: Randomized comparison to placebo and sublingual buprenorphine\/naloxone","volume":"108","author":"Rosenthal","year":"2013","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0400","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jama.2016.9382","article-title":"Effect of buprenorphine implants on illicit opioid use among abstinent adults with opioid dependence treated with sublingual buprenorphine: A randomized clinical trial","volume":"316","author":"Rosenthal","year":"2016","journal-title":"Journal of the American Medical Association (JAMA)"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0405","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<267::AID-HEC511>3.0.CO;2-H","article-title":"The veil of experience: Do consumers prefer what they know best?","volume":"9","author":"Salkeld","year":"2000","journal-title":"Health Economics"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0410","doi-asserted-by":"crossref","first-page":"24s","DOI":"10.1177\/0033354918793627","article-title":"A public health strategy for the opioid crisis","volume":"133","author":"Saloner","year":"2018","journal-title":"Public Health Reports"},{"issue":"12","key":"10.1016\/j.jsat.2020.01.009_bb0415","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.3109\/10826089909039423","article-title":"Injectable methadone prescribing in the United Kingdom: Current practice and future policy guidelines","volume":"34","author":"Sarfraz","year":"1999","journal-title":"Substance Use and Misuse"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0420","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1007\/s11135-017-0574-8","article-title":"Saturation in qualitative research: Exploring its conceptualization and operationalization","volume":"52","author":"Saunders","year":"2018","journal-title":"Quality and Quantity"},{"key":"10.1016\/j.jsat.2020.01.009_bb0425","doi-asserted-by":"crossref","unstructured":"Saunders, E., Metcalf, S. A., Walsh, O., Moore, S. K., Meier, A., McLeman, B., \u2026 Marsch, L. A. (2019a). \"You can see those concentric rings going out\": Emergency personnel's experiences treating overdose and perspectives on policy-level responses to the opioid crisis in New Hampshire. Drug and Alcohol Dependence, 204, 107555. doi:https:\/\/doi.org\/10.1016\/j.drugalcdep.2019.107555.","DOI":"10.1016\/j.drugalcdep.2019.107555"},{"key":"10.1016\/j.jsat.2020.01.009_bb0430","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-019-05232-y","article-title":"Screening for substance use in rural primary care: A qualitative study of providers and patients","author":"Saunders","year":"2019","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.jsat.2020.01.009_bb0435","series-title":"Atlas.Ti, version 7. Berlin, GER","author":"Scientific Software Development GmbH","year":"2013"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0440","article-title":"Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder","volume":"43","author":"Shi","year":"2018","journal-title":"Journal of Psychiatry and Neuroscience"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0445","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1503\/jpn.170036","article-title":"Effects of extended-release naltrexone on the brain response to drug-related stimuli in patients with opioid use disorder","volume":"43","author":"Shi","year":"2018","journal-title":"Journal of Psychiatry and Clinical Neuroscience"},{"key":"10.1016\/j.jsat.2020.01.009_bb0450","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40834-016-0011-8","article-title":"LARC methods: Entering a new age of contraception and reproductive health","volume":"1","author":"Shoupe","year":"2016","journal-title":"Contraceptive and Reproductive Medicine"},{"key":"10.1016\/j.jsat.2020.01.009_bb0455","doi-asserted-by":"crossref","unstructured":"Sordo, L., Barrio, G., Bravo, M. J., Indave, B. I., Degenhardt, L., Wiessing, L., \u2026 Pastor-Barriuso, R. (2017). Mortality risk during and after opioid substitution treatment: Systematic review and meta-analysis of cohort studies. The British Journal of Medicine, 357, j1550. doi:https:\/\/doi.org\/10.1136\/bmj.j1550.","DOI":"10.1136\/bmj.j1550"},{"key":"10.1016\/j.jsat.2020.01.009_bb0460","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jsat.2016.11.003","article-title":"Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement","volume":"73","author":"Stumbo","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.01.009_bb0465","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)"},{"key":"10.1016\/j.jsat.2020.01.009_bb0470","series-title":"Medications for opioid use disorder: For healthcare and addiction professionals, policymakers, patients, and families","article-title":"SAMHSA\/CSAT treatment improvement protocols","author":"Substance Abuse and Mental Health Services Administration (SAMHSA)","year":"2018"},{"issue":"10","key":"10.1016\/j.jsat.2020.01.009_bb0475","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s40263-013-0110-x","article-title":"Extended-release intramuscular naltrexone (VIVITROL(R)): A review of its use in the prevention of relapse to opioid dependence in detoxified patients","volume":"27","author":"Syed","year":"2013","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0480","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s13561-017-0162-6","article-title":"Discrete-choice modelling of patient preferences for modes of drug administration","volume":"7","author":"Tetteh","year":"2017","journal-title":"Health Econonics Review"},{"issue":"1499","key":"10.1016\/j.jsat.2020.01.009_bb0485","first-page":"94","article-title":"Buprenorphine implants (Probuphine) for opioid dependence","volume":"58","author":"The Medical Letter","year":"2016","journal-title":"Medical Letter and Drugs and Therapeutics"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0490","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1080\/10550887.2016.1100960","article-title":"Retention in medication-assisted treatment for opiate dependence: A systematic review","volume":"35","author":"Timko","year":"2016","journal-title":"Journal of Addictive Disease"},{"issue":"4","key":"10.1016\/j.jsat.2020.01.009_bb0495","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMsr1706626","article-title":"The role of science in addressing the opioid crisis","volume":"377","author":"Volkow","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10.1016\/j.jsat.2020.01.009_bb0500","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMp1402780","article-title":"Medication-assisted therapies: Tackling the opioid-overdose epidemic","volume":"370","author":"Volkow","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.jsat.2020.01.009_bb0505","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: A randomized clinical trial","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"10.1016\/j.jsat.2020.01.009_bb0510","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.drugpo.2014.07.009","article-title":"Prescription opioid misuse in the United States and the United Kingdom: Cautionary lessons","volume":"25","author":"Weisberg","year":"2014","journal-title":"The International Journal on Drug Policy"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2020.01.009_bb0515","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2009.03.008","article-title":"Open-label dose-finding trial of buprenorphine implants (Probuphine)\u00ae for treatment of heroin dependence","volume":"103","author":"White","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/00952990.2018.1546862","article-title":"Development of a cascade of care for responding to the opioid epidemic","volume":"45","author":"Williams","year":"2019","journal-title":"American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2020.01.009_bb0525","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","article-title":"Developing an opioid use disorder treatment cascade: A review of quality measures","volume":"91","author":"Williams","year":"2018","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.01.009_bb0530","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cct.2016.07.013","article-title":"Design of the NIDA clinical trials network validation study of tobacco, alcohol, prescription medications, and substance use\/misuse (TAPS) tool","volume":"50","author":"Wu","year":"2016","journal-title":"Contemporary Clinical Trials"},{"issue":"1","key":"10.1016\/j.jsat.2020.01.009_bb0535","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/biores.2017.0037","article-title":"Patient-perceived atonomy and long-acting reversible contraceptive use: A qualitative assessment in a Midwestern, university community","volume":"7","author":"Zeal","year":"2018","journal-title":"Bioresearch Open Access"},{"issue":"3","key":"10.1016\/j.jsat.2020.01.009_bb0540","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1359105307088142","article-title":"Patient satisfaction and sustained outcomes of drug abuse treatment","volume":"13","author":"Zhiwei","year":"2008","journal-title":"Journal of Health Psychology"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219303885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547219303885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:51:17Z","timestamp":1760039477000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547219303885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":108,"alternative-id":["S0740547219303885"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.01.009","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.01.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}